OTCMKTS:EMIS Emisphere Technologies (EMIS) Stock Price, News & Analysis → Elon’s New A.I. Device is About to Shock the World (From InvestorPlace) (Ad) Free EMIS Stock Alerts $7.81 0.00 (0.00%) (As of 12/9/2020) Add Compare Share Share Today's Range$7.81▼$7.8150-Day Range$7.81▼$7.8152-Week Range$4.06▼$9.16VolumeN/AAverage Volume75,743 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Emisphere Technologies alerts: Email Address Ad InvestorPlaceHave You Seen Elon’s New A.I. Device? (Picture Inside)A strange new era for mankind is upon us... And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day. Elon believes A.I. is advancing so fast...This strange new device to protect us against that A.I. threat... About Emisphere Technologies Stock (OTCMKTS:EMIS)Emisphere Technologies, Inc. operates as a commercial stage pharmaceutical and drug delivery company in the United States. The company offers oral Eligen B12 Rx, an oral formulation prescription medical food for use by B12 deficient individuals. It is also developing GLP-1, which is in Phase III clinical trial for the treatment of type 2 diabetes and related conditions. The company's preclinical programs focus on the development of oral formulations for the treatment of diabetes; and products in the areas of cardiovascular, appetite suppression, and pain, as well as in the development and expansion of nutritional supplement products. It has license agreements with Novo Nordisk A/S to develop and commercialize oral formulations of GLP-1 receptor agonists in combination with Emisphere carriers, as well as to develop and commercialize oral formulations of Novo Nordisk's insulin using the company's Eligen Technology. The company was formerly known as Clinical Technologies Associates, Inc. and changed its name to Emisphere Technologies, Inc. in 1991. Emisphere Technologies, Inc. was founded in 1986 and is based in Roseland, New Jersey.Read More EMIS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EMIS Stock News HeadlinesMarch 3, 2024 | ca.finance.yahoo.comExco Technologies Limited (XTC.TO)December 11, 2023 | dailymail.co.ukInsulin pill could free diabetics from jabsApril 29, 2024 | InvestorPlace (Ad)Elon’s New A.I. Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” November 19, 2023 | barrons.comSHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Emisphere Technologies, Inc. with Losses of $100,000 to Contact the FirmOctober 23, 2023 | businesswire.comEMIS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Emisphere Technologies, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!October 5, 2023 | benzinga.comEntwistle & Cappucci LLP Files a Securities Class Action Complaint Against Emisphere Technologies, Inc.May 8, 2023 | finance.yahoo.comBuccal Drug Delivery System Global Market Report 2023May 4, 2023 | msn.comFlying high on obesity success, Novo's appetite for deals growsApril 29, 2024 | InvestorPlace (Ad)Elon’s New A.I. Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” April 16, 2023 | marketwatch.comInformative Market Research Report on Thrombin Inhibitor with Estimated CAGR of 12.5% from 2023-2030April 11, 2023 | uk.finance.yahoo.comOral Biologics & Biosimilars Global Market Report 2023March 2, 2023 | marketwatch.comIncretin-Based Drugs Market Size Regional Analysis 2023 which includes Rapid Growth Rate Till 2025February 19, 2023 | marketwatch.comGlobal Non-insulin Diabetes Therapeutics Market Size Analysis, Share, Application, Opportunities Forecast to 2030 By VMReportsFebruary 14, 2023 | marketwatch.comInsulin Detemir Market 2023 Size, Share, Applications, Advance Technology And Top Companies To 2026September 23, 2022 | benzinga.comOral Biologics & Biosimilars Global Market Report 2022July 20, 2022 | benzinga.comDiabetes Devices Market Size is projected to reach USD 49.25 Billion by 2030, growing at a CAGR of 6.62%: Straits ResearchMarch 10, 2022 | marketwatch.comOral Drug Delivery Market Analysis, Key Players, Segmentation, Application And rate of 7.60% in the forecast period of 2022 to 2029February 24, 2022 | za.investing.comEmisphere Tech (EMIS)February 22, 2022 | fool.comEmisphere Technologies, Inc.(EMIS)January 17, 2022 | thestreet.comHealth Stocks in MotionDecember 19, 2021 | law360.comLaw360 Pulse's Spotlight On Mid-Law WorkNovember 18, 2021 | bloomberg.comFormer NFL Quarterback, MLB Pitcher Chad Hutchinson is Now a Sports PE ExecutiveNovember 18, 2021 | law360.com3 Firms Lead Novo Nordisk's $3.3B Dicerna BuyNovember 4, 2021 | marketwatch.comNovo Nordisk's New Obesity Drug Boosted 3Q Earnings -- Earnings ReviewOctober 15, 2021 | law360.comCounsel In $1.8B Biotech Sale Suit Urged To Work TogetherSeptember 23, 2021 | marketwatch.comThrombin Inhibitors Market Trends, Size, Market Share, Growth Factor, Opportunities, Segment, Top Manufacturers, Drivers and Forecast 2021-2026September 7, 2021 | law360.comLead Counsel Battle Heats Up In $1.8B Biotech Sale SuitSee More Headlines Receive EMIS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Emisphere Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/12/2017Today4/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:EMIS CUSIPN/A CIK805326 Webwww.emisphere.com Phone973-532-8000Fax973-422-0125Employees6Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Alan L. Rubino (Age 65)Advisor Mr. Alan V. Gallantar CPA (Age 62)Interim Chief Financial Officer Key CompetitorsAbliva AB (publ)OTCMKTS:NEVPFAcusphereOTCMKTS:ACUSAddex TherapeuticsOTCMKTS:ADDXFAeolus PharmaceuticalsOTCMKTS:AOLSAffymaxOTCMKTS:AFFYView All Competitors EMIS Stock Analysis - Frequently Asked Questions How have EMIS shares performed in 2024? Emisphere Technologies' stock was trading at $7.81 on January 1st, 2024. Since then, EMIS shares have increased by 0.0% and is now trading at $7.81. View the best growth stocks for 2024 here. How were Emisphere Technologies' earnings last quarter? Emisphere Technologies, Inc. (OTCMKTS:EMIS) announced its quarterly earnings data on Friday, May, 12th. The company reported $0.04 EPS for the quarter. The firm earned $0.22 million during the quarter. What other stocks do shareholders of Emisphere Technologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Emisphere Technologies investors own include Novo Nordisk A/S (NVO), Fulcrum Therapeutics (FULC), VIVUS (VVUS), Allena Pharmaceuticals (ALNA), Capricor Therapeutics (CAPR), Aldeyra Therapeutics (ALDX), CymaBay Therapeutics (CBAY), Cerecor (CERC) and Cumberland Pharmaceuticals (CPIX). How do I buy shares of Emisphere Technologies? Shares of EMIS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:EMIS) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe #1 Biotech Stock to Have on Your Radar in 2024… Huge AlertsAI finds its first serious applicationWall Street StarHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Emisphere Technologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
